6533b85efe1ef96bd12c09cb
RESEARCH PRODUCT
IVIG in APS pregnancy
Antonino PerinoAngelo FerranteCadelo MFrancesco CicciaGiovanni TrioloGiuseppe LicataAntonio CastelliA Accardo-palumbosubject
medicine.medical_specialtyAbortion Habitual030204 cardiovascular system & hematologyrecurrent fetal losslaw.invention03 medical and health sciences0302 clinical medicineRheumatologyRandomized controlled trialAntiphospholipid syndromelawPregnancyhemic and lymphatic diseasesInternal medicinemedicineHigh dosesHumans030203 arthritis & rheumatologyIVIGPregnancybiologybusiness.industryPregnancy Complications HematologicImmunoglobulins IntravenousThrombosisHeparinmedicine.diseaseAntiphospholipid SyndromeThrombosisPregnancy ComplicationsImmune Globulin TherapyImmunologybiology.proteinFemaleAntibodybusinessmedicine.drugAPSdescription
For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as ‘IVIG’) has benefited patients with a variety of autoimmune disorders. A potential therapeutic role of IVIG in the prevention of thrombosis and of miscarriages in antiphospholipid syndrome (APS) has been postulated. Multicenter randomized controlled trials attempted to define the role of IVIG in preventing pregnancy complications in APS indicate that simple anticoagulation could not be completely satisfactory, and certain patient subgroups might take advantage of IVIG therapy alone or in combination with heparin.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2004-01-01 |